Amena Khatun Manica has been honored with the Excellence in Drug Design Research Award – 2025 at the Fourth International Conference on Transformative Innovations in Science, Technology, Nursing and Medical Sciences (NEXTGEN TECH 2025), held on December 29–30, 2025. The prestigious recognition was jointly conferred by Eudoxia Research University, USA, and Kanyakumari Medical Mission College & Research Centre, Tamil Nadu, India.
Manica’s research stood out among a large number of international submissions for its depth, originality, and strong alignment with the conference’s focus on transformative innovation in medical and pharmaceutical sciences. Her award-winning work centers on computational drug design and data-driven drug discovery, integrating molecular modeling, artificial intelligence, and advanced analytics to accelerate the identification and optimization of therapeutic candidates. Through in-silico screening and predictive modeling, her research addresses key challenges in modern drug development, including time efficiency, cost reduction, and improved accuracy in decision-making.
The event, which brought together participants from more than 5 countries, among more than 50 participants, only six individuals were honored across all award categories in this Conference. Manica’s selection underscores the global relevance of his work and the high level of competitiveness surrounding the awards.
The NEXTGEN TECH 2025 award evaluation process was conducted by a distinguished international committee comprising senior academic leaders and industry experts. The committee was led by Chief Patron Prof. Dr. Rhituraj Saikia, President, Eudoxia Research University, USA, and Patron Prof. Dr. Caleb Moyo, Vice Chancellor, Eudoxia Research University, USA. The evaluation was convened by Prof. Dr. Dimitrios A. Karras, National and Kapodistrian University of Athens, Greece, with Dr. Edward Haberek Jr., Professor, DeVry University, Arlington, USA, serving as Organizing Secretary.
Manica received the award in recognition of her innovative integration of computational chemistry, artificial intelligence, and pharmaceutical data analytics in drug discovery research. The evaluation committee highlighted her originality, methodological rigor, and ability to translate complex scientific concepts into practical, scalable solutions for healthcare research and development.
The global impact of Manica’s research lies in its scalability and international applicability. Her methodologies can be adopted by academic institutions and pharmaceutical companies worldwide. By contributing to faster and more efficient drug discovery pipelines, her work supports global efforts toward improved therapeutic development. The Excellence in Drug Design Research Award – 2025 marks a significant milestone in her professional journey and highlights the growing international impact of research contributions originating from Bangladesh and the United States.
